Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Winner of Qualcomm Tricorder XPrize Unveiled at AACC

By LabMedica International staff writers
Posted on 08 Jun 2017
A highlight of the July 30 - August 3, 2017, AACC Annual Scientific Meeting & Clinical Lab Expo (San Diego, CA, USA) will be the session dedicated to the unveiling of the winner of the Qualcomm Tricorder XPrize (Culver City, CA, USA) competition.

The 10 million USD global competition, which was announced in 2012, challenged 34 research teams to produce a lightweight device (a "tricorder") that consumers could have at their fingertips to diagnose a health condition or monitor their vital signs without the need to consult a medical professional. More...
To qualify the device had to be capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms).

In the science-fictional Star Trek universe, a tricorder was a multifunction hand-held device used for sensor scanning, data analysis, and recording data. The standard tricorder was a general-purpose device used primarily to scout unfamiliar areas, make detailed examination of living things, and record and review technical data. The medical tricorder was used by doctors to help diagnose diseases and collect bodily information about a patient; the key difference between this and a standard tricorder was a detachable hand-held high-resolution scanner stored in a compartment of the tricorder when not in use.

The winner of the top prize of 2.6 million USD was Final Frontier Medical Devices, a Pennsylvania-based team led by Dr. Basil Harris, an emergency medicine physician, and his brother George Harris, a network engineer, for their artificial intelligence-based engine, DxtER, which learns to diagnose medical conditions by integrating learnings from clinical emergency medicine with data analysis from actual patients.

DxtER was designed to monitor the individual's health and diagnose illnesses away from the hospital or doctor's office setting. DxtER functions autonomously, but can also share important information with healthcare providers. At the heart of DxtER is an artificially intelligent engine that learned to diagnose by integrating years of experience in clinical emergency medicine with data analysis from actual patients having a variety of medical conditions and outcomes. Included with DxtER is an assortment of non-invasive sensors custom-designed to collect data about vital signs, body chemistry, and biological functions. The diagnostic engine synthesizes the health data to make a quick and accurate assessment.

Dynamical Biomarkers Group was awarded the second place in the Qualcomm Tricorder XPRIZE competition for their prototype, which links diagnostic algorithms with analytical methodology in a user-friendly device, all controlled through a smartphone.

Final Frontier Medical Devices team member Philip Charron and Dynamical Biomarkers Group team member Dr. Chung-Kang Peng will describe their revolutionary technologies in a major session at the 69th AACC Annual Scientific Meeting.

Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
Qualcomm Tricorder XPrize


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.